Osteosarcopenic obesity syndrome (OSO)
Approved Research ID: 95862
Approval date: February 8th 2023
Osteosarcopenic obesity syndrome (OSO) is a cluster of three conditions: reduced bone health (Osteoporosis), reduced of muscle mass (sarcopenia), and overweight (obesity). Each condition represents a severe consequence for the individual and society with negative health effects including risk of fractures, physical disability, insulin resistance, increased risk of infection, increased length of hospital stay, and increased mortality. The annual costs of treating bone fracture, overweight, and reduced muscle mass are enormous in addition to the potential risk of non-infectious diseases associated with obesity (e.g., type II diabetes, hypertension, stroke, cancer, cardiovascular disease).
Still, whether the negative health consequences of having two or three of the conditions in OSO are beyond only having one conditions, are not known. Furthermore, the knowledge of prevalence, cause and consequences of having OSO are limited. Therefore, the aim of present project is to examine the prevalence of OSO, two conditions or only one condition using the UK Biobank database.
The project will last until 2030 and hopefully we will increase the knowledge of the prevalence, cause, and generate possible rehabilitation and prevention strategies for people with the OSO syndrome.